Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04413383
Other study ID # 2023744
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 21, 2020
Est. completion date July 14, 2021

Study information

Verified date August 2021
Source University of Missouri-Columbia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Every year thousands of dermatologic surgery procedures are performed at the University of Missouri Department of Dermatology, including Mohs Micrographic Surgery (MMS), Excisions, and biopsies. Surgery is known to cause anxiety for patients and with these procedures performed under local anesthetic on awake patients', the sights, sounds, and smells experienced during the procedure can lead to an increase in their anxiety or affect their overall perception of the experience. From performing and assisting with dermatologic surgery the noise associated with the use of the traditional curved Iris scissors provokes an increase in patient awareness to the procedure resulting in increased anxiety, triggering of the vasovagal response, and expressions of annoyance by the patient. However, the modified curved Iris scissors make almost no noise. The Investigators hypothesize that if patients were given the comparative experience of both types of curved Iris scissors during dermatologic surgery, then they will choose the modified curved Iris scissors because the lack of noise will be perceived as more pleasant experience. Our objective is to perform a prospective, single blinded, randomized controlled trial to determine how the noise of traditional curved Iris scissors vs the silent Wuennenberg modified curved Iris scissors affects patients during dermatologic surgery.


Recruitment information / eligibility

Status Completed
Enrollment 147
Est. completion date July 14, 2021
Est. primary completion date July 14, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult (18 years or older) - non-pregnant - patients being treated with Mohs micrographic surgery or excision on the head and neck Exclusion Criteria: - Patients not meeting above inclusion criteria will be excluded.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Traditional Curved Iris Scissors
Aesculap Curved Iris Scissors
Wuennenberg Modified Curved Iris Scissors
Modified Silent Curved Iris Scissors
Comparative Experience of Traditional and Wuennenberg Modified Curved Iris Scissors
Patients experience both types of scissors

Locations

Country Name City State
United States UPMB Columbia Missouri

Sponsors (1)

Lead Sponsor Collaborator
University of Missouri-Columbia

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Extent that patient notices curved Iris scissors Questionnaire with an ordinal scale from 1 to 10 to assess the extent that patient notices the use of the curved iris scissors. 3 to 8 hours (length of the patients Mohs Surgery)
Primary Extent that patient is bothered by the curved Iris scissors Questionnaire with an ordinal scale from 1 to 10 to assess the extent that patient is bothered by the curved iris scissors. 3 to 8 hours (length of the patients Mohs Surgery)
Primary Patients Preference of curved Iris scissor Patient is asked during the procedure if they prefer "1," surgeon uses the traditional curved Iris scissors, or "2" and the surgeon uses the Wuennenberg modified curved Iris scissors. The patient indicates their preference by responding "1 or 2." After the procedure the patient completes a questionnaire with an ordinal scale from 1 to 10 to assess the extent that patient notices and is bothered by the curved iris scissors. 3 to 8 hours (length of the patients Mohs Surgery)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02721459 - XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma Phase 1
Completed NCT03740815 - Feasibility of Serratus Plane Block Associated With Sedation in Axillary Dissection N/A
Recruiting NCT05779423 - Cryoablation+Ipilimumab+Nivolumab in Melanoma Phase 2
Terminated NCT01468818 - Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma Phase 2
Completed NCT01820234 - Evaluation of Store-and-Forward Teledermatology Versus a Face-to-Face Assessment During a Skin Cancer Screening Event N/A
Completed NCT00535769 - Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use Phase 0
Completed NCT00526032 - Melanoma Detection by Oblique-Incidence Optical Spectroscopy N/A
Completed NCT00588341 - Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection Phase 2
Active, not recruiting NCT01447199 - The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)
Enrolling by invitation NCT04758988 - AI Augmented Training for Skin Specialists N/A
Not yet recruiting NCT04534868 - Patient Acceptance And Satisfaction of Teledermoscopy In General Practice In a Belgian Rural Area N/A
Recruiting NCT04138342 - Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer Phase 1
Completed NCT03673917 - Cosmetology Students and Skin Cancer N/A
Recruiting NCT04341064 - Sun-safe Habits Intervention and Education Phase 3
Completed NCT04206995 - Cancer Sensing: Evaluation of Odour Sampling Techniques
Recruiting NCT05574101 - A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer Phase 2
Not yet recruiting NCT05860881 - Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin) Phase 3
Completed NCT05146622 - Virtual Sun Safe Workplaces Ph I
Recruiting NCT05068310 - Applicability of a Cellular Resolution Full-field OCT Image System for Pigmented and Non-pigmented Skin Tumors
Recruiting NCT03889899 - Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia. N/A